$-0.14 EPS Expected for NovoCure Limited (NVCR)

February 16, 2018 - By Adrian Erickson

 $ 0.14 EPS Expected for NovoCure Limited (NVCR)

Analysts expect NovoCure Limited (NASDAQ:NVCR) to report $-0.14 EPS on February, 22.They anticipate $0.12 EPS change or 46.15 % from last quarter’s $-0.26 EPS. After having $-0.13 EPS previously, NovoCure Limited’s analysts see 7.69 % EPS growth. The stock increased 1.65% or $0.35 during the last trading session, reaching $21.5. About 149,391 shares traded. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since February 16, 2017 and is downtrending. It has underperformed by 17.13% the S&P500.

NovoCure Limited (NASDAQ:NVCR) Ratings Coverage

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. The rating was initiated by JMP Securities on Tuesday, October 27 with “Market Outperform”. The firm earned “Outperform” rating on Tuesday, October 27 by Wedbush. JP Morgan initiated it with “Overweight” rating and $29 target in Tuesday, October 27 report. Wedbush maintained NovoCure Limited (NASDAQ:NVCR) on Friday, July 29 with “Outperform” rating. The stock of NovoCure Limited (NASDAQ:NVCR) earned “Hold” rating by Deutsche Bank on Wednesday, December 2. The firm has “Underweight” rating by Barclays Capital given on Tuesday, January 19.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $1.92 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

More recent NovoCure Limited (NASDAQ:NVCR) news were published by: Nasdaq.com which released: “NovoCure Reaches Analyst Target Price” on September 14, 2017. Also Nasdaq.com published the news titled: “NovoCure Ltd is Now Oversold” on October 13, 2017. Fool.com‘s news article titled: “Here’s Why NovoCure Ltd. Is Skyrocketing Today” with publication date: April 03, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: